Denali Therapeutics Inc (NASDAQ:DNLI) – Investment analysts at Wedbush issued their FY2021 EPS estimates for Denali Therapeutics in a research note issued to investors on Thursday, November 7th. Wedbush analyst L. Chico expects that the company will post earnings per share of ($2.66) for the year. Wedbush currently has a “Neutral” rating and a $19.00 target price on the stock. Wedbush also issued estimates for Denali Therapeutics’ FY2022 earnings at ($2.74) EPS and FY2023 earnings at ($2.69) EPS.
Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.08. The business had revenue of $13.60 million for the quarter, compared to analysts’ expectations of $10.86 million. Denali Therapeutics had a negative net margin of 40.78% and a negative return on equity of 11.03%.
Other equities analysts also recently issued reports about the stock. Nomura assumed coverage on shares of Denali Therapeutics in a report on Friday, September 13th. They set a “buy” rating and a $35.00 price target on the stock. Morgan Stanley set a $32.00 price target on shares of Denali Therapeutics and gave the company a “buy” rating in a report on Friday, August 9th. BTIG Research assumed coverage on shares of Denali Therapeutics in a report on Friday, August 9th. They set a “buy” rating and a $30.00 price target on the stock. HC Wainwright reiterated a “buy” rating on shares of Denali Therapeutics in a report on Thursday, August 8th. Finally, ValuEngine upgraded shares of Denali Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company’s stock. Denali Therapeutics has a consensus rating of “Buy” and an average price target of $27.25.
Shares of NASDAQ DNLI traded down $0.70 during mid-day trading on Friday, hitting $14.82. 534,600 shares of the company’s stock traded hands, compared to its average volume of 353,763. The company’s 50-day moving average is $15.81 and its two-hundred day moving average is $19.12. The company has a debt-to-equity ratio of 0.15, a current ratio of 10.65 and a quick ratio of 10.66. The company has a market capitalization of $1.58 billion, a P/E ratio of -38.00 and a beta of 2.14. Denali Therapeutics has a 1 year low of $14.24 and a 1 year high of $28.86.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State Board of Administration of Florida Retirement System boosted its stake in shares of Denali Therapeutics by 19.3% during the second quarter. State Board of Administration of Florida Retirement System now owns 20,555 shares of the company’s stock valued at $427,000 after purchasing an additional 3,330 shares in the last quarter. Xact Kapitalforvaltning AB bought a new position in shares of Denali Therapeutics during the second quarter valued at approximately $210,000. Baillie Gifford & Co. boosted its stake in shares of Denali Therapeutics by 18.3% during the second quarter. Baillie Gifford & Co. now owns 7,407,229 shares of the company’s stock valued at $153,773,000 after purchasing an additional 1,145,003 shares in the last quarter. Acadian Asset Management LLC boosted its stake in shares of Denali Therapeutics by 136.7% during the second quarter. Acadian Asset Management LLC now owns 11,650 shares of the company’s stock valued at $241,000 after purchasing an additional 6,728 shares in the last quarter. Finally, Chicago Equity Partners LLC bought a new position in shares of Denali Therapeutics during the second quarter valued at approximately $2,438,000. Hedge funds and other institutional investors own 73.91% of the company’s stock.
In other Denali Therapeutics news, CEO Ryan J. Watts sold 8,581 shares of the company’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $18.05, for a total value of $154,887.05. Following the transaction, the chief executive officer now directly owns 12,505 shares in the company, valued at approximately $225,715.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Alexander O. Schuth sold 7,500 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.16, for a total transaction of $136,200.00. 21.20% of the stock is owned by corporate insiders.
About Denali Therapeutics
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.
Further Reading: How is a Moving Average Calculated?
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.